Gilead Sciences Inc at JPMorgan Healthcare Conference Transcript
Good morning, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Gilead today. From the company, we're going to have a presentation from Dan O'Day, Chairman and CEO, and we're going to follow that presentation with a Q&A session with the broader management team.
So with that, I'll turn it over to Dan. I look forward to the updates here. Thank you.
' -
Thank you very much. Terrific. So good morning, everybody. Welcome to JPMorgan. Delighted to be here with the team, and really delighted to kind of update you on the Gilead growth story in 2026 and beyond.
Maybe just before I get into the presentation, I just thought back to reflect upon what an important year 2025 was for us. And I'll get into it in more detail. But obviously, the launch of lenacapavir caught the world's attention and was extraordinarily important for us, and we feel the responsibility in that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
